Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Jan;23(1):50-8.
doi: 10.1177/2047487314544046. Epub 2014 Jul 29.

Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial

Robert Wolk  1 , Marnie Bertolet  2 , Maria M Brooks  2 , Richard E Pratley  3 , Burton E Sobel  4 , Robert L Frye  5 , Prachi Singh  5 , Andrew D Calvin  5 , Martin K Rutter  6 , Arshag D Mooradian  7 , Virend K Somers  5 ; BARI 2D study group
Affiliations
Randomized Controlled Trial

Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial

Robert Wolk et al. Eur J Prev Cardiol. 2016 Jan.

Abstract

Aims: To determine the effects of insulin sensitization (IS) and insulin provision (IP) treatment strategies on adipokines associated with cardiovascular disease in patients with type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D).

Methods and results: Changes in adipokine levels were compared in patients with type 2 diabetes mellitus and coronary artery disease randomized to IS (n = 1037) versus IP (n = 1019) treatment strategies in BARI 2D. Circulating concentrations of leptin, adiponectin, monocyte chemoattractant protein-1, tumor necrosis factor-alpha, interleukin 6 and C-reactive protein were evaluated at baseline and one year. IS and IP treatment strategies exerted significant (p < 0.0001) differential effects on: leptin (IS: 0.02% decrease, p = 0.01; IP: 13% increase, p < 0.0001); adiponectin (IS: 73% increase, p < 0.0001; IP: no change, p = 0.52); interleukin 6 (IS: 14% decrease, p < 0.0001; IP: no change, p = 0.68). Changes in monocyte chemoattractant protein-1 and tumor necrosis factor-alpha were not statistically different between groups. C-reactive protein decreased, but the effect was significantly greater in the IS group (-32%, p < 0.0001) than in the IP group (-5%, p = 0.0005).

Conclusion: The IS and IP treatment strategies exerted divergent effects on adipokine and inflammatory profile in patients with type 2 diabetes mellitus and coronary artery disease. The IS treatment strategy-induced changes may be more favorable than the IP treatment strategy regarding cardiovascular pathophysiology.

Keywords: Diabetes mellitus; adipokines; coronary disease; risk factors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
First year change in adipokines by sex, logged then standardized based on baseline sex (mean and SD).
See this image and copyright information in PMC

References

    1. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation. 2003;108(13):1541–5. - PubMed
    1. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004;33(2):283–303. - PubMed
    1. Agewall S, Fagerberg B, Attvall S, Wendelhag I, Urbanavicius V, Wikstrand J. Carotid artery wall intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. Stroke. 1995;26(6):956–60. - PubMed
    1. Bressler P, Bailey SR, Matsuda M, DeFronzo RA. Insulin resistance and coronary artery disease. Diabetologia. 1996;39(11):1345–50. - PubMed
    1. Howard G, O’Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R, The Insulin Resistance Atherosclerosis Study (IRAS) Investigators Insulin sensitivity and atherosclerosis. Circulation. 1996;93(10):1809–17. - PubMed

Publication types

MeSH terms